
    
      In this prospective study, there is only one group with no placebo/blank control. All
      qualified IBS-D patients could be admitted to hospital for at least one time of combing
      therapy (taking rifaximin for 3 days and then receiving fecal microbiota transplantation) and
      follow-up until 6 months after the first treatment.
    
  